scholarly journals Comparative analysis of genomic alterations in lymph node, bone and visceral metastases in castration resistant prostate cancer

2020 ◽  
Vol 19 ◽  
pp. e1827-e1828
Author(s):  
A. Ali ◽  
A.M. Haran ◽  
C.A. Hart ◽  
M.D. Brown ◽  
N.W. Clarke
Keyword(s):  
Prostate Cancer ◽  
Lymph Node ◽  
Comparative Analysis ◽  
Castration Resistant Prostate Cancer ◽  
Genomic Alterations ◽  
Castration Resistant ◽  
Visceral Metastases

scholarly journals Radium-223 for the treatment of patients with castration-resistant prostate cancer with bone metastases

2018 ◽  
pp. 78-82
Author(s):  
A. D. Kaprin ◽  
A. A. Kostin ◽  
N. V. Vorobyev ◽  
S. V. Popov
Keyword(s):  
Prostate Cancer ◽  
Bone Metastases ◽  
Efficacy And Safety ◽  
Castration Resistant Prostate Cancer ◽  
Good Tolerability ◽  
Development Of Resistance ◽  
Castration Resistant ◽  
Radium 223 ◽  
Visceral Metastases ◽  
Bone Complications

The development of resistance to endocrine therapy and the tumor progression in patients with prostate cancer are associated with an unfavourable prognosis. The article presents a review of clinical trials of efficacy and safety, as well as the experience in using radioisotope radium-223 chloride in clinical practice in patients with castration-resistant prostate cancer with bone metastases without visceral metastases. It was shown that radium-223 chloride therapy in this category of patients leads to an increase in overall survival and time to the development of bone complications, and is characterized by good tolerability.

scholarly journals Highlighting the Place of Metastasis-Directed Therapy in Isolated Liver Metastases in Prostate Cancer: A Case Report

2021 ◽  
Vol 11 ◽  
Author(s):  
Anne-Emmanuella Yeo ◽  
Aurore Hendrix ◽  
Caterina Confente ◽  
Nicolas Christian ◽  
Baudouin Mansvelt ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Liver Metastases ◽  
Poor Prognosis ◽  
Prostate Cancer Patient ◽  
Abiraterone Acetate ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistant ◽  
Visceral Metastases ◽  
Isolated Liver

Metastatic prostate cancer remains a challenge for clinicians. Metastases involve mainly the bone compartment and can manifest as oligometastatic disease. In this setting, the role of metastasis-directed therapies (MDT) including surgery and/or stereotactic body radiotherapy is currently evaluated. Visceral metastases are less common and have very poor prognosis in mPC. Whether treating isolated visceral metastases such as liver metastases with MDT could increase the prognosis remains unknown. We report the management of a prostate cancer patient who progressed on androgen deprivation therapy with apparition of two liver metastases. We describe the feasibility of combining MDT with abiraterone acetate and prednisone in a patient with metastatic castration-resistant prostate cancer. MDT allowed the interruption of abiraterone acetate, preventing cumulative toxicity of this agent.

Abiraterone acetate treatment in patients with castration-resistant prostate cancer with visceral metastases

2019 ◽  
Vol 30 (2) ◽  
pp. 179-185 ◽  
Author(s):  
Gaetano Facchini ◽  
Carla Cavaliere ◽  
Carmine D’Aniello ◽  
Gelsomina Iovane ◽  
Sabrina Rossetti
Keyword(s):  
Prostate Cancer ◽  
Abiraterone Acetate ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistant ◽  
Visceral Metastases
Sign in / Sign up

Export Citation Format

Share Document